Patients with thyroid eye disease (TED) who received fewer than the standard 8-dose regimen of teprotumumab achieve a significant reduction in proptosis, clinical activity score (CAS), and extraocular muscle restriction, according to a study.
Interruptions in treatment were due to a temporary halt in teprotumumab production due to the coronavirus (COVID-19) pandemic vaccine effort. The current study shows that improvements were maintained until the interruption was over.
Of the 74 patients included in the study, 62 were in the active phase and 12 had minimal to no clinical activity. There was an average of 4.2 teprotumumab infusions before the interruption.
In patients in active phase, there was a significant mean reduction in proptosis of -2.9 mm; in patients with no clinical activity, there was a significant mean reduction -2.8 mm.
A 3.4-point reduction in CAS and reduction in ocular motility restriction were maintained during the interruption in patients with active disease.
Reference
Ho TC, Maamari RN, Kossler AL, et al. Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab. Ophthalmic Plast Reconstr Surg. 2022;doi: 10.1097/IOP.0000000000002267. Epub ahead of print. PMID: 36095848.
Related Content
